Sab biotherapeutics receives an additional $8.2 million in closeout of dod contract

Sioux falls, s.d., jan. 18, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that the company has received an additional $8.2 million from the u.s. department of defense (dod) related to the closeout of the discontinued covid-19 prototype research and development contract. this brings the total final closeout settlement to $16.8 million received since november 2022.
SABS Ratings Summary
SABS Quant Ranking